Pfizer implements $1.5bn cost-cutting initiative. Idea 27/05/24
Pfizer Inc. (PFE) has announced a new multi-year plan to reduce operational costs by approximately 1.5 billion USD by the end of 2027. This initiative is in addition to a previously announced 4 billion USD cost reduction strategy in response to decreased investments and a sharp decline in sales from its COVID-19 vaccine. Amid these challenges, Pfizer has actively restructured its operations, including acquiring cancer drug manufacturer Seagen for 43 billion USD, aiming to diversify and strengthen its product portfolio.
Despite these financial adjustments, Pfizer has raised its full-year earnings forecast following better-than-expected earnings in Q1. These results were partly attributed to the successful implementation of cost-saving measures. To bolster its financial standing, the company focuses on operational efficiency, restructuring its network, and enhancing its product portfolio.
Given this backdrop, let's examine the potential trading opportunities for Pfizer Inc. (NYSE: PFE):
On the Daily (D1) timeframe, Pfizer's stock shows a resistance level at 29.65 USD and support at 28.45 USD. The resistance line of the ongoing downtrend has been breached, suggesting a potential shift in market sentiment. If the trend reverses downward, a possible target might be 25.30 USD.
If the current uptrend persists, a short-term target is 31.90 USD upon rebounding from the 29.65 USD resistance level. For a medium-term strategy, the stock price could reach 34.10 USD if the upward momentum continues.
—
Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews.
The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments.
Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69.88% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Despite these financial adjustments, Pfizer has raised its full-year earnings forecast following better-than-expected earnings in Q1. These results were partly attributed to the successful implementation of cost-saving measures. To bolster its financial standing, the company focuses on operational efficiency, restructuring its network, and enhancing its product portfolio.
Given this backdrop, let's examine the potential trading opportunities for Pfizer Inc. (NYSE: PFE):
On the Daily (D1) timeframe, Pfizer's stock shows a resistance level at 29.65 USD and support at 28.45 USD. The resistance line of the ongoing downtrend has been breached, suggesting a potential shift in market sentiment. If the trend reverses downward, a possible target might be 25.30 USD.
If the current uptrend persists, a short-term target is 31.90 USD upon rebounding from the 29.65 USD resistance level. For a medium-term strategy, the stock price could reach 34.10 USD if the upward momentum continues.
—
Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews.
The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments.
Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69.88% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
